Full-Time

Data Analyst

Advanced Analytics

ClearView Healthcare Partners

ClearView Healthcare Partners

501-1,000 employees

Life sciences strategy consulting for biopharma

No salary listed

Noida, Uttar Pradesh, India

In Person

On-site role based in Gurgaon; remote work not available.

Bachelor's

Category
Data & Analytics (1)
Required Skills
SAS
Neural Networks
SQL
Machine Learning
Data Analysis
Excel/Numbers/Sheets

Get referred to ClearView Healthcare Partners

See people who can refer or advise you

Requirements
  • Bachelor’s degree or above in Statistics, Mathematics, Machine Learning, Physics, or a related field.
  • Relevant experience of 1-3 years working on insurance claims and EHR databases – IQVIA (LAAD), Komodo (Sentinel), Forian, Compile and others.
  • Experience with large data manipulation in SAS or SQL interfaces.
  • Experience with life science APIs & public datasets (e.g., PubMed, OpenTrials, CMS, CDC, etc.).
  • Experience in at least one of the following areas: Excel modeling (using a spreadsheet to make quantitative predictions based on a series of underlying assumptions).
  • Common machine learning models (e.g., neural networks, support vector machines, decision trees).
  • Advanced regression models (e.g., Bayesian, hierarchical, non-linear).
  • Unsupervised learning.
  • Advanced time series.
  • Detail-oriented with the ability to dive deep into business processes, data, and analytics.
  • Independent, creative, and driven quantitative thinker.
  • Role is based out of our Gurgaon, India office.
Responsibilities
  • Collect, clean, mine, and analyze data.
  • Serve as a knowledge resource for the consulting staff regarding statistics, machine learning, and life sciences data.
  • Design and create advanced models to drive analytically driven strategy projects.
  • Innovate project approaches and identify new life sciences problems to solve with analytics.
  • Aid in team building by making code scalable through templates, macros, or interfaces.
  • Clearly communicate analytical techniques and findings from analyses in a non-technical manner.
  • Work in a high-performance, strongly collegial, and collaborative environment.
ClearView Healthcare Partners

ClearView Healthcare Partners

View

ClearView Healthcare Partners provides strategic consulting services exclusively for the life sciences sector, guiding pharmaceutical, biotechnology, medical devices, and diagnostics firms through decisions from discovery to commercialization. It completes project work with 100% of a dedicated team focused on a single client engagement, pairing rigorous scientific knowledge with business strategy, with many consultants holding life sciences PhDs. The firm differentiates itself through its strict one-client-per-project model, sector-only focus, and deep scientific expertise, plus international expansion to serve global clients. Its goal is to help life sciences companies grow, advance product development, and secure market access, creating value across the entire product lifecycle.

Company Size

501-1,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Newton, Massachusetts

Founded

2008

Get referred to ClearView Healthcare Partners

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ClearView invested $4 million in Epistemic AI on January 10, 2025.
  • The March 2026 Salesforce-driven expert-network overhaul improves screening, scheduling, and compensation.
  • Seven open roles and 2026 hiring across Boston, London, San Francisco, and Gurgaon signal demand.

What critics are saying

  • Epistemic AI integration exposes ClearView to expensive technology bets if adoption stalls.
  • Expert-network Salesforce changes in March 2026 can disrupt delivery and consultant utilization.
  • AI tools commoditize strategy decks, squeezing premium advisory pricing by 2027.

What makes ClearView Healthcare Partners unique

  • 100% dedicated project teams keep ClearView focused on one client engagement at a time.
  • PhD-heavy consultants and founders from McKinsey, Leerink, and banking anchor scientific credibility.
  • London and Zurich offices, opened by 2026, deepen cross-border biopharma coverage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Remote Work Options

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Holidays

Flexible Work Hours

Wellness Program

Mental Health Support

Professional Development Budget

Conference Attendance Budget

Stock Options

Company Equity

Family Planning Benefits

Fertility Treatment Support

Home Office Stipend

Phone/Internet Stipend

Parental Leave

Adoption Assistance

Meal Benefits

Relocation Assistance

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

12%
PR Newswire
Mar 12th, 2025
The Addf'S Diagnostics Accelerator Authors New Paper On Ocular Biomarker Landscape, Highlighting Ocular Tests As A Tool For Early Detection Of Alzheimer'S Disease

New findings published in Alzheimer's Dementia suggest blood biomarkers are expected to become the standard method for diagnosing Alzheimer's, while ocular tests offer a non-invasive alternative for detecting at-risk patient populations NEW YORK, March 12, 2025 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA) authored a first-of-its-kind paper, "Unlocking ocular biomarkers for early detection of Alzheimer's disease," providing a landscape review of ocular biomarkers as another tool, alongside blood biomarkers, to aid in the early detection of Alzheimer's disease. The paper, which was published in Alzheimer's Dementia, shares an informed perspective on the role of ocular biomarkers in the broader Alzheimer's diagnostics space and what defines a true ocular biomarker, while also highlighting the potential for ocular screening to identify at-risk patients who would otherwise go undiagnosed. The authors' assessment is based on hours of in-depth interviews with leading neurologists, ophthalmologists, optometrists, and primary care physicians from across the United States

Citybiz
Jan 13th, 2025
ClearView Invests $4M in Epistemic AI

ClearView Healthcare Partners announced a $4 million minority investment in Epistemic AI to enhance its EpistemicGPT platform, which combines AI with a vast biomedical knowledge graph. This partnership aims to improve ClearView's service offerings by integrating AI technology, enhancing research and drug development processes. The collaboration underscores a commitment to advancing biomedical research and healthcare outcomes through innovative technology solutions.

Citybiz
Jan 13th, 2025
ClearView Healthcare Partners Invest In Epistemic AI

BOSTON, MA and WESTPORT, CT – 13 January 2025: ClearView Healthcare Partners, the leading life sciences strategic consultancy supporting Pharma... Read More

Digital Therapeutics Alliance
Nov 15th, 2023
DTx Commercialization Launch Playbook Case Study

Digital Therapeutics Alliance is thrilled to announce the release of its latest white paper in collaboration with Clearview Healthcare Partners!

Foundation Fighting Blindness
Feb 13th, 2023
The Foundation's long-term impact on moving the inherited retinal disease field forward towards treatments and cures. — Foundation Fighting Blindness

The Foundation Fighting Blindness partnered with ClearView Healthcare Partners to evaluate the impact of its funding and resources since 2005 on the clinical understanding and development of novel therapies for inherited retinal diseases (IRDs).